In a recent bridge to transplantation approach in two infant B-ALL patients, use of TALENs to generate universal CAR-T cells (UCART) by knockout of TRAC coupled with CD52 knockout to endow resistance to the monoclonal antibody Alemtuzumab (Campath), which is used to eliminate CD52+ lymphocytes, was shown to be feasible (101). Here, CD52 is linked to acute lymphoblastic leukemia.